The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | PROs in the Beamion LUNG-1 of zongertinib in HER2-mutated NSCLC
Joshua Sabari, MD, New York University Langone Health, New York, NY, comments on the benefits of HER2-directed therapies in non-small cell lung cancer (NSCLC). A significant reduction in patients’ symptoms related to respiratory status, as well as improvements in functional status and quality of life, with no additional toxicity were reported in the Phase Ia/Ib Beamion LUNG-1 trial (NCT04886804) of zongertinib. These patient-reported outcomes (PROs) are particularly valuable given the high risk of toxicity associated with prior therapies. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We know that with HER2-directed therapies, patient-reported outcomes are going to be critical because prior therapies have had a high risk of toxicity. Some of our chemotherapy options, such as in HER2, have high rates of fatigue, potential nausea, diarrhea, alopecia, and hair loss. And some of our prior HER2-directed therapies that were not specific for HER2 also had EGFR inhibition with high rates of diarrhea as well as rash...
We know that with HER2-directed therapies, patient-reported outcomes are going to be critical because prior therapies have had a high risk of toxicity. Some of our chemotherapy options, such as in HER2, have high rates of fatigue, potential nausea, diarrhea, alopecia, and hair loss. And some of our prior HER2-directed therapies that were not specific for HER2 also had EGFR inhibition with high rates of diarrhea as well as rash. Here, our patient-reported outcomes, we saw a significant reduction in patients’ symptoms related to respiratory status. So within one week, dramatic improvements. We also saw a significant improvement in patients’ functional status and quality. And being a member of the trial and enrolling patients on the study, we’ve seen a significant improvement despite no additional toxicity for patients. So it’s an exciting therapeutic for patients in the future.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consulting or Advisory Role – Abbvie; AstraZeneca; Genentech/Roche; Janssen; Janssen (Inst); Loxo/Lilly; Loxo/Lilly (Inst); Medscape; Mirati Therapeutics; Mirati Therapeutics (Inst); Pfizer; Regeneron; Regeneron (Inst); Sanofi; Takeda
